SRC and colorectal adenocarcinoma: Dasatinib, a small molecule tyrosine kinase inhibitor that targets various tyrosine kinases, especially the Src family [43], was applied to treat colorectal adenocarcinoma HT29 and SW620 cell lines, which exhibited high expression of Src.